Sign in
4

Changes in Ownership

Xenon Pharmaceuticals Inc. Filed Acc 0000950170-25-009388

PRESIDENT & CEO sold 55,000 shares at an average $40.25 ($2,213,997)

  • PRESIDENT & CEO acquired 55,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

MORTIMER IAN · PRESIDENT & CEO

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2025-01-23 Exercise or conversion : show line 1 in the form 10b5-1 +16,217 $17.76 $288,014 47,519 D
2025-01-23 Sale : show line 2 in the form 10b5-1 −16,217 $40.08 $649,977 31,302 D
2025-01-24 Exercise or conversion : show line 3 in the form 10b5-1 +22,468 $17.76 $399,032 53,770 D
2025-01-24 Sale : show line 4 in the form 10b5-1 −22,468 $40.20 $903,214 31,302 D
2025-01-27 Exercise or conversion : show line 5 in the form 10b5-1 +15,166 $17.76 $269,348 46,468 D
2025-01-27 Sale : show line 6 in the form 10b5-1 −15,166 $40.46 $613,616 31,302 D
2025-01-27 Exercise or conversion : show line 7 in the form 10b5-1 +1,149 $17.76 $20,406 32,451 D
2025-01-27 Sale : show line 8 in the form 10b5-1 −1,149 $41.07 $47,189 31,302 D
Open-market sales · 55,000 sh · avg $40.25 · $2,213,997

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-01-23 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) −16,217 38,783 D
2025-01-24 Exercise or conversion : show line 10 in the form 10b5-1 Stock Option (Right to Buy) −22,468 16,315 D
2025-01-27 Exercise or conversion : show line 11 in the form 10b5-1 Stock Option (Right to Buy) −16,315 0 D
Loading xslF345X05/ownership.xml…